Edding Genor (HKG: 6998) announced that China’s National Medical Products Administration (NMPA) has approved two investigational new drug (IND) applications for GB268, the company’s highly differentiated PD‑1/CTLA‑4/VEGF trispecific antibody: a Phase Ib/II clinical trial of GB268 as monotherapy or in combination therapy for metastatic (stage IV) non‑small cell lung cancer (NSCLC), and a Phase II/III clinical trial of GB268 combined with chemotherapy as first‑line treatment for locally advanced or metastatic biliary tract cancer (BTC) not amenable to curative surgical resection.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | IND clearances (two trials) |
| Product | GB268 – PD‑1/CTLA‑4/VEGF trispecific antibody |
| Trial 1 | Phase Ib/II – GB268 monotherapy or combination therapy in metastatic (stage IV) NSCLC |
| Trial 2 | Phase II/III – GB268 + chemotherapy, first‑line, locally advanced or metastatic BTC not amenable to curative surgical resection |
| Announcement Date | 16 Nov 2026 |
| Trial Design Details | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: GB268, a highly differentiated and innovative trispecific antibody simultaneously engaging three targets.
- Targets: PD‑1 (T‑cell checkpoint), CTLA‑4 (T‑cell priming checkpoint), and VEGF (angiogenesis driver) — combining dual immune checkpoint blockade with anti‑angiogenic activity in a single molecule.
- Mechanistic Effects: Designed to improve the tumour immune microenvironment, promote T‑cell infiltration, and inhibit angiogenesis.
- Differentiation Potential: The tri‑targeting design carries the potential to overcome immunotherapy resistance, a central limitation of existing PD‑1/PD‑L1 monotherapies.
- Administration: Antibody format; dosing and schedule details were not disclosed.
Expanded Clinical Pipeline in China
- Breast Cancer (previously cleared): GB268 received approval in China for a Phase Ib/II clinical trial in locally advanced unresectable or metastatic breast cancer, including triple‑negative breast cancer (TNBC) and hormone receptor‑positive/HER2‑negative breast cancer.
- Colorectal Cancer (previously cleared): GB268 also holds approval for a Phase II clinical trial in combination with chemotherapy as first‑line treatment for advanced colorectal cancer.
- Portfolio Breadth: With the two new INDs, GB268 is now cleared for clinical development across four major solid tumor indications — NSCLC, BTC, breast cancer, and colorectal cancer — spanning both monotherapy and combination settings.
Market Impact & Outlook
- NSCLC Landscape: Metastatic NSCLC remains the largest solid‑tumor indication for checkpoint inhibitors; a trispecific combining PD‑1/CTLA‑4 blockade with VEGF inhibition enters a competitive field where checkpoint‑plus‑anti‑angiogenic combinations are an active frontier.
- BTC First‑Line Opportunity: Biliary tract cancer has limited first‑line options beyond gemcitabine/cisplatin‑based chemotherapy with or without immunotherapy; a Phase II/III first‑line combination trial positions GB268 for a potential standard‑of‑care contest.
- Trispecific Modality Trend: Multi‑specific antibodies that fuse checkpoint blockade with anti‑angiogenesis are attracting strong development interest in China, and GB268’s four‑indication footprint makes it one of the broader trispecific programs disclosed to date.
- Resistance‑Focused Positioning: If the immune‑microenvironment‑remodeling rationale holds clinically, GB268 could address patients who progress on existing PD‑1/PD‑L1 therapies — though no clinical efficacy data have been disclosed to date.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development of GB268, trial initiation and execution in NSCLC and BTC, safety and efficacy outcomes, and potential future regulatory submissions. Actual results may differ due to risks including trial enrollment and conduct, clinical and immunogenicity outcomes, regulatory review requirements, and competitive dynamics in the checkpoint inhibitor and multi‑specific antibody markets. No clinical data, dosing details, or development timelines have been disclosed.-Fineline Info & Tech
